{"entity":{"id":"nct06634875","kind":"trial","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","aka":[],"tldr":"A phase 2 trial of isunakinra in colorectal cancer, run by Buzzard Pharmaceuticals, now recruiting.","summary":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) is a phase 2 interventional study registered as NCT06634875 by Buzzard Pharmaceuticals, with 20 participants planned, started 2025-01-30 and due to reach its primary completion in 2026-06. Interventions recorded: isunakinra.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06634875","url":"https://clinicaltrials.gov/study/NCT06634875"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06634875","phase":"2","setting":"A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination With Pembrolizumab in Patients With Metastatic or Unresectable, Locally Advanced Colorectal Cancer","sponsor":"Buzzard Pharmaceuticals","started":"2025-01-30","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06634875/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}